News Releases

May 11, 2023
Biodesix Announces First Quarter 2023 Results and Highlights
   First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET   BOULDER, Colo.
Apr 27, 2023
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
BOULDER, Colo. --(BUSINESS WIRE)--Apr. 27, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May
Feb 28, 2023
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
BOULDER, Colo. --(BUSINESS WIRE)--Feb. 28, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will participate in a fireside chat and host in-person 1x1